This content is for healthcare professionals only.

An independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.

Faculty & Disclosures

Listen on the go
    • Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Martin Weber

    University Medical Center Göttingen, Germany

    Prof. Martin Weber is a classical clinician–scientist with a goal of translating high-class basic science into new therapeutic approaches for the treatment of multiple sclerosis (MS). 

    At the University Medical Center Göttingen (UMG), Germany, Prof. Weber feels blessed with a unique setting to pursue this vision. As a tenured associate professor, he heads a large, entirely independent research group of scientists and physicians at the world-renowned Institute of Neuropathology, where they develop the experimental basis for a continuous improvement of therapeutic options for MS. read more

    On the clinical side, Prof. Weber heads the section of inflammatory central nervous system disorders in the Department of Neurology, including a large outpatient clinic, a specialized MS day clinic and an independent laboratory for cerebrospinal fluid analyses, providing first-class MS patient care for the entire region of southern Lower Saxony. 

    An interdisciplinary clinical MS centre has recently been established at the University of Göttingen, which combines scientific and clinical institutions working in the field of MS and related diseases. As the newly appointed head of this centre, Prof. Weber is in the privileged position to develop a clinical programme that can directly trial promising new therapies derived from their own laboratory and from the extended, traditionally strong, neuroscientific environment in Göttingen. 

    Prof. Martin Weber has no interests/relationships or affiliations to disclose in relation to this activity.
    Back to Faculty
    touchNEUROLOGY touchNEUROLOGY
    SEE ALL VIDEOS
    Start activity
     
    Expert Interviews
    Multiple Sclerosis, Neuroimmunology CE/CME accredited

    touchEXPERT OPINIONS
    Experts answer questions with in-depth advice on the current clinical landscape and how new therapies and guidance might impact regional clinical practice. Useful tips below will show how to navigate the activity. Close

    Optimizing the management of patients with relapsing forms of MS: An update on emerging treatment options

    Take CE/CME Test

    Prof. Martin Weber is a classical clinician–scientist with a goal of translating high-class basic science into new therapeutic approaches for the treatment of multiple sclerosis (MS). 

    At the University Medical Center Göttingen (UMG), Germany, Prof. Weber feels blessed with a unique setting to pursue this vision. As a tenured associate professor, he heads a large, entirely independent research group of scientists and physicians at the world-renowned Institute of Neuropathology, where they develop the experimental basis for a continuous improvement of therapeutic options for MS. read more

    On the clinical side, Prof. Weber heads the section of inflammatory central nervous system disorders in the Department of Neurology, including a large outpatient clinic, a specialized MS day clinic and an independent laboratory for cerebrospinal fluid analyses, providing first-class MS patient care for the entire region of southern Lower Saxony. 

    An interdisciplinary clinical MS centre has recently been established at the University of Göttingen, which combines scientific and clinical institutions working in the field of MS and related diseases. As the newly appointed head of this centre, Prof. Weber is in the privileged position to develop a clinical programme that can directly trial promising new therapies derived from their own laboratory and from the extended, traditionally strong, neuroscientific environment in Göttingen. 

    Prof. Martin Weber has no interests/relationships or affiliations to disclose in relation to this activity.

    Take CE/CME Test

    Prof. Martin Weber is a classical clinician–scientist with a goal of translating high-class basic science into new therapeutic approaches for the treatment of multiple sclerosis (MS). 

    At the University Medical Center Göttingen (UMG), Germany, Prof. Weber feels blessed with a unique setting to pursue this vision. As a tenured associate professor, he heads a large, entirely independent research group of scientists and physicians at the world-renowned Institute of Neuropathology, where they develop the experimental basis for a continuous improvement of therapeutic options for MS. read more

    On the clinical side, Prof. Weber heads the section of inflammatory central nervous system disorders in the Department of Neurology, including a large outpatient clinic, a specialized MS day clinic and an independent laboratory for cerebrospinal fluid analyses, providing first-class MS patient care for the entire region of southern Lower Saxony. 

    An interdisciplinary clinical MS centre has recently been established at the University of Göttingen, which combines scientific and clinical institutions working in the field of MS and related diseases. As the newly appointed head of this centre, Prof. Weber is in the privileged position to develop a clinical programme that can directly trial promising new therapies derived from their own laboratory and from the extended, traditionally strong, neuroscientific environment in Göttingen. 

    Prof. Martin Weber has no interests/relationships or affiliations to disclose in relation to this activity.

    Take CE/CME Test

    Prof. Martin Weber is a classical clinician–scientist with a goal of translating high-class basic science into new therapeutic approaches for the treatment of multiple sclerosis (MS). 

    At the University Medical Center Göttingen (UMG), Germany, Prof. Weber feels blessed with a unique setting to pursue this vision. As a tenured associate professor, he heads a large, entirely independent research group of scientists and physicians at the world-renowned Institute of Neuropathology, where they develop the experimental basis for a continuous improvement of therapeutic options for MS. read more

    On the clinical side, Prof. Weber heads the section of inflammatory central nervous system disorders in the Department of Neurology, including a large outpatient clinic, a specialized MS day clinic and an independent laboratory for cerebrospinal fluid analyses, providing first-class MS patient care for the entire region of southern Lower Saxony. 

    An interdisciplinary clinical MS centre has recently been established at the University of Göttingen, which combines scientific and clinical institutions working in the field of MS and related diseases. As the newly appointed head of this centre, Prof. Weber is in the privileged position to develop a clinical programme that can directly trial promising new therapies derived from their own laboratory and from the extended, traditionally strong, neuroscientific environment in Göttingen. 

    Prof. Martin Weber has no interests/relationships or affiliations to disclose in relation to this activity.

    Take CE/CME Test
    Podcast Featured
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Recognize processes for reliable and early identification of individuals with MS at high risk of transition to secondary progressive MS
    • Discuss the evidence for B cells in the pathogenesis and progression of MS
    • Appraise the efficacy and safety of approved and emerging therapeutic agents for relapsing forms of MS that target B cells
    Overview

    In this activity, a leading multiple sclerosis (MS) specialist shares key considerations for a personalized treatment strategy for patients with relapsing forms of MS (RMS), and goes on to explore the key role that B cells play in the pathogenesis and progression of MS, including the therapeutic potential of B-cell–targeted agents.

    This activity is jointly provided by USF Health and touchIME. read more

    Target Audience

    Neurologists and MS specialists involved in the management of patients with RMS.

    Disclosures

    USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.

    Faculty

    Prof. Martin Weber has no interests/relationships or affiliations to disclose in relation to this activity.

    Content reviewer

    John Robert Ciotti, MD, discloses: Advisory board or panel fees from EMD Serono, Genentech, Janssen and Novartis (all relationships terminated).

    Touch Medical Contributors

    Christina Mackins-Crabtree has no financial interests/relationships or affiliations to disclose in relation to this activity.

    USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

    Requirements for Successful Completion

    In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

    If you have questions regarding credit please contact cpdsupport@usf.edu.

    Accreditations

    Physicians

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

    USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

    Advanced Practice Providers

    Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

    The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.

    Date of original release: 07 December 2023. Date credits expire: 07 December 2024.

    If you have any questions regarding credit please contact cpdsupport@usf.edu.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    touchIN CONVERSATION

    Early diagnosis and treatment of NMOSD: Practical insights

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    Lifestyle Measures in Multiple Sclerosis

    GO TO ARTICLE

    touchEXPERT OPINIONS

    Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    Discontinuation of Disease-modifying Treatments in Relapsing-remitting Multiple Sclerosis – A Systematic Literature Review of Observational Studies

    GO TO ARTICLE
    Assessing Cognitive Changes.png

    CONFERENCE HUB

    Assessing Cognitive Changes

    GO TO HUB
    ECR on demand_Kilsdonk.png

    CONFERENCE HUB

    ECR On Demand Preview: Neuroinflammation and infectious diseases – SS 1811b, B-1012 (I.D. Kilsdonk)

    GO TO HUB

    Topics covered in this activity

    Multiple Sclerosis / Neuroimmunology
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 10 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    This Activity Is Funded By:

    An independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 07 December 2023. Date credits expire: 07 December 2024.

    Claim Credit
    touchEXPERT OPINIONS
    Optimizing the management of patients with relapsing forms of MS: An update on emerging treatment options
    0.75 CE/CME credit
    Question 1/5
    Your 37-year-old female patient with relapsing MS presents at your clinic feeling frustrated and confused. Despite achieving NEDA in her follow-up, she is still experiencing progressive and persistent symptoms such as fatigue, pain and cognitive difficulties. How would you manage this patient?

    MS, multiple sclerosis; NEDA, no evidence of disease activity; QoL, quality of life

    The goal of MS therapy is the best possible disease control and the best possible QoL for the patient. In practice, disease control must be measured by clinical parameters (especially relapses and disability) and MRI activity (the so-called NEDA concept).1 There are limitations to NEDA in clinical practice, in that it may not capture subtle changes in inflammation and neurodegeneration that underlie disability.2 MRI results must be considered in tandem with the broader clinical picture to encompass patient symptoms and neurological exam changes, which are important elements that contribute to a clearer understanding of the overall disease activity status.2

    Abbreviations

    MRI, magnetic resonance imaging; MS, multiple sclerosis; NEDA, no evidence of disease activity; QoL, quality of life.

    References

    1. Wiendl H, et al. Ther Adv Neurol Disord. 2021:14;17562864211039648.
    2. Newsome SD, et al. Neurol Ther. 2023;12:1909–35.
    Question 2/5
    BTK has emerged as a target of interest for B-cell function modulation during MS. How would you describe the rationale for modulating BTK in a patient with MS?

    BCR, B-cell receptor; BTK, Bruton's tyrosine kinase; MS, multiple sclerosis.

    Unlike anti-CD20 therapy, BTK inhibition reportedly disrupts B-cell maturation and signalling without causing widespread B-cell depletion. This is a potentially important benefit, as B-cell depletion can induce humoral immunosuppression that can impair the humoral response to vaccination and increase the risk of infection, such as COVID-19.

    Abbreviations

    BTK, Bruton’s tyrosine kinase; CD, cluster of differentiation.

     

    Reference

    Evonuk KS, et al. Acta Neuropathol Commun. 2023;11:115.

    Question 3/5
    Which of the following statements highlights a difference between BTK inhibitors and anti-CD20 agents for the treatment of MS?

    BBB, blood–brain barrier; BTK, Bruton's tyrosine kinase; CD, cluster of differentiation; MS, multiple sclerosis.

    BTK inhibitors differ in several ways compared to CD20 agents due to their relatively small size. For example, BKT inhibitors are able to cross the BBB, which is crucial for the efficacy in treating the CNS compartmentalized immune response involved in the pathogenesis of progressive types of MS.

    Abbreviations:

    BBB, blood–brain barrier; BTK, Bruton’s tyrosine kinase; CD, cluster of differentiation; CNS, central nervous system; MS, multiple sclerosis.

    Reference:

    Saberi D, et al. Expert Opin Ther Targets. 2023;27:347–59.

    Question 4/5
    You are in the process of prescribing an anti-CD20 monoclonal antibody to your 55-year-old male patient living with relapsing MS? What would you advise about most likely adverse events?

    CD, cluster of differentiation; MS, multiple sclerosis.

    Infusion-/injection-related reactions are the most common adverse events reported in patients treated with anti-CD20 monoclonal antibodies. Administration-related reactions generally occur within 24 hours of the first injection/infusion and decrease with subsequent doses.

    Abbreviation:

    CD, cluster of differentiation.

    Reference: 

    de Séze J, et al. Front Immunol. 2023:14;1004795.

     

    Question 5/5
    Which of the following are phase III trials that have met their primary endpoints in terms of demonstrating efficacy of anti-CD20 antibodies in relapsing MS?

    BTK, Bruton’s tyrosine kinase; CD, cluster of differentiation.

    OPERA,1 ASCLEPIOS2 and ULTIMATE3 are all phase III trials evaluating the efficacy of the anti-CD20 antibodies, ocrelizumab, ofatumumab and ublituximab, respectively, in patients with RMS.

    Abbreviations:
    CD, cluster of differentiation; RMS, relapsing multiple sclerosis.

    References:

    1. Hauser SL, et al. N Engl J Med. 2017;376:221–34.
    2. Hauser SL, et al. N Engl J Med. 2020;383:546–57.
    3. Steinman L, et al. N Engl J Med. 2022;387:704–14.
    Back to Activity

    You may also be interested in...

    touchIN CONVERSATION

    Early diagnosis and treatment of NMOSD: Practical insights

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    JOURNALS

    Foreword: touchREVIEWS in Neurology, Volume 20, Issue 1, 2024

    GO TO ARTICLE

    CONFERENCE HUB

    Enrique Alvarez, AAN 2023: Disease outcomes with ublituximab in participants with highly active disease from subpopulation analyses of the phase III ULTIMATE I and II studies in participants with relapsing multiple sclerosis

    GO TO HUB

    touchEXPERT OPINIONS

    Disease-modifying therapies in multiple sclerosis: Current perspectives on the latest data

    This activity is CE/CME accredited
    LAUNCH ACTIVITY
    Advances in Multiple Sclerosis (MS) Treatment

    CONFERENCE HUB

    Advances in Multiple Sclerosis (MS) Treatment

    GO TO HUB

    JOURNALS

    Application of Interferon Beta-1b in Multiple Sclerosis

    GO TO ARTICLE
    This Activity Is Funded By:

    An independent medical education grant from Sanofi. This activity is jointly provided by USF Health and touchIME.

    The information provided by this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

    USF is an Equal Opportunity / Affirmative Action / Equal Access Institution.

    USF Health is accredited by the Accreditation Council for Continuing Medical Education, the American Nurses Credentialing Center and the Accreditation Council for Pharmacy Education to provide continuing education to healthcare professionals. As an accredited provider, USF Health is required to disclose personal information to relevant accredited bodies that certify CME to process credits/contact hours, comply with reporting requirements, and for internal recordkeeping and regulatory purposes. USF Health does not share or sell any individual’s contact information or unique identifiers to any commercial supporter, advertiser, or third party without the specific permission of the individual.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME and USF Health to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME or USF Health of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME or USF Health activities. touchIME and USF Health accept no responsibility for errors or omissions.

    This content is intended for healthcare professionals.

    Date of original release: 07 December 2023. Date credits expire: 07 December 2024.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72